Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03641755 | Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | active not recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07190469 | PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | recruiting | Phase 1 | 80 | ProteinQure Inc.INDUSTRY | 2 | Feb 23, 2026 | clinicaltrials |
| NCT07423117 |
| A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy |
| not yet recruiting |
| Phase 1 |
| 102 |
| IntoCell, IncINDUSTRY |
| 0 |
| Feb 20, 2026 |
| clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02157051 | Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer | active not recruiting | Phase 1 | 42 | University of WashingtonOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05074290 | Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 74 | University of FloridaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07208149 | A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 42 | Shenzhen Majory Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 220 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05383196 | Onvansertib + Paclitaxel In TNBC | active not recruiting | Phase 1 / Phase 2 | 50 | Antonio Giordano, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06064812 | A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. | recruiting | Phase 1 / Phase 2 | 99 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05504707 | DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer(DecipHER) | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07390838 | A Study of SH009 Injection in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06171607 | Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses | recruiting | Phase 1 | 100 | University of Southern CaliforniaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT04150042 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells(SHARON) | recruiting | Phase 1 | 24 | General Oncology, Inc.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07370506 | Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 36 | Tanta UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05968144 | Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness(ADRIAN) | active not recruiting | Phase 1 / Phase 2 | 30 | University of Maryland, BaltimoreOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06715826 | Target-specific immunoPET Imaging of Breast Cancer | recruiting | Phase 1 / Phase 2 | 200 | RenJi HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT02779751 | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | active not recruiting | Phase 1 | 100 | Eli Lilly and CompanyINDUSTRY | 7 | Jan 26, 2026 | clinicaltrials |
| NCT06324240 | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | University of Alabama at BirminghamOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05556473 | F-Tryptophan PET/CT in Human Cancers | recruiting | Phase 1 | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03863457 | [18F] F-GLN by PET/CT in Breast Cancer([18F]F-GLN) | recruiting | Phase 1 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT06503783 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06609187 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06738966 | A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer | recruiting | Phase 1 | 9 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07336771 | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 60 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02284919 | [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer(ISO-1Primary) | active not recruiting | Phase 1 | 30 | University of PennsylvaniaOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07002177 | A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC | recruiting | Phase 1 / Phase 2 | 196 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT07274852 | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06596018 | Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy | recruiting | Phase 1 / Phase 2 | 96 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07292142 | FMT in Triple Negative Breast Cancer Guided by ctDNA(FRIDA) | not yet recruiting | Phase 1 / Phase 2 | 125 | Jewish General HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06375187 | A Study of GC203 TIL in Advanced Malignant Solid Tumors(KUNLUN-001) | recruiting | Phase 1 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT06238921 | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | recruiting | Phase 1 / Phase 2 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2026source: clinicaltrials